|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011.
|
|
2
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108.
2005.
|
|
3
|
Venook AP, Papandreou C, Furuse J and de
Guevara LL: The incidence and epidemiology of hepatocellular
carcinoma: a global and regional perspective. Oncologist. 15(Suppl
4): S5–S13. 2010.
|
|
4
|
Zhu AX, Chabner BA and Tanabe KK: New
trends and novel treatment for hepatocellular carcinoma: a global
perspective. Oncologist. 15(Suppl 4): S1–S4. 2010.
|
|
5
|
Bengochea A, de Souza MM, Lefrançois L, et
al: Common dysregulation of Wnt/Frizzled receptor elements in human
hepatocellular carcinoma. Br J Cancer. 99:143–150. 2008.
|
|
6
|
Camilli TC and Weeraratna AT: Striking the
target in Wnt-y conditions: intervening in Wnt signaling during
cancer progression. Biochem Pharmacol. 80:702–711. 2010.
|
|
7
|
Liu H, Fergusson MM, Wu JJ, et al: Wnt
signaling regulates hepatic metabolism. Sci Signal. 4:ra62011.
|
|
8
|
MacDonald BT, Tamai K and He X:
Wnt/beta-catenin signaling: components, mechanisms, and diseases.
Dev Cell. 17:9–26. 2009.
|
|
9
|
Uematsu K, He B, You L, Xu Z, McCormick F
and Jablons DM: Activation of the Wnt pathway in non small cell
lung cancer: evidence of dishevelled overexpression. Oncogene.
22:7218–7221. 2003.
|
|
10
|
Segditsas S and Tomlinson I: Colorectal
cancer and genetic alterations in the Wnt pathway. Oncogene.
25:7531–7537. 2006.
|
|
11
|
Urakami S, Shiina H, Enokida H, et al:
Combination analysis of hypermethylated Wnt-antagonist family genes
as a novel epigenetic biomarker panel for bladder cancer detection.
Clin Cancer Res. 12:2109–2116. 2006.
|
|
12
|
Thompson MD and Monga SP: WNT/beta-catenin
signaling in liver health and disease. Hepatology. 45:1298–1305.
2007.
|
|
13
|
Yook JI, Li XY, Ota I, et al: A
Wnt-Axin2-GSK3beta cascade regulates Snail1 activity in breast
cancer cells. Nat Cell Biol. 8:1398–1406. 2006.
|
|
14
|
Bovolenta P, Esteve P, Ruiz JM, Cisneros E
and Lopez-Rios J: Beyond Wnt inhibition: new functions of secreted
Frizzled-related proteins in development and disease. J Cell Sci.
121:737–746. 2008.
|
|
15
|
Marsit CJ, Karagas MR, Andrew A, et al:
Epigenetic inactivation of SFRP genes and TP53 alteration act
jointly as markers of invasive bladder cancer. Cancer Res.
65:7081–7085. 2005.
|
|
16
|
Nojima M, Suzuki H, Toyota M, et al:
Frequent epigenetic inactivation of SFRP genes and constitutive
activation of Wnt signaling in gastric cancer. Oncogene.
26:4699–4713. 2007.
|
|
17
|
Takagi H, Sasaki S, Suzuki H, et al:
Frequent epigenetic inactivation of SFRP genes in hepatocellular
carcinoma. J Gastroenterol. 43:378–389. 2008.
|
|
18
|
Kawakami K, Yamamura S, Hirata H, et al:
Secreted frizzled-related protein-5 is epigenetically downregulated
and functions as a tumor suppressor in kidney cancer. Int J Cancer.
128:541–550. 2011.
|
|
19
|
Shepard CW, Simard EP, Finelli L, Fiore AE
and Bell BP: Hepatitis B virus infection: epidemiology and
vaccination. Epidemiol Rev. 28:112–125. 2006.
|
|
20
|
Capurro MI, Xiang YY, Lobe C and Filmus J:
Glypican-3 promotes the growth of hepatocellular carcinoma by
stimulating canonical Wnt signaling. Cancer Res. 65:6245–6254.
2005.
|
|
21
|
Lee HC, Kim M and Wands JR: Wnt/Frizzled
signaling in hepatocellular carcinoma. Front Biosci. 11:1901–1915.
2006.
|
|
22
|
Bovolenta P, Rodriguez J and Esteve P:
Frizzled/RYK mediated signalling in axon guidance. Development.
133:4399–4408. 2006.
|
|
23
|
Cheng YY, Yu J, Wong YP, et al: Frequent
epigenetic inactivation of secreted frizzled-related protein 2
(SFRP2) by promoter methylation in human gastric cancer. Br J
Cancer. 97:895–901. 2007.
|
|
24
|
Suzuki H, Gabrielson E, Chen W, et al: A
genomic screen for genes upregulated by demethylation and histone
deacetylase inhibition in human colorectal cancer. Nat Genet.
31:141–149. 2002.
|
|
25
|
Suzuki H, Watkins DN, Jair KW, et al:
Epigenetic inactivation of SFRP genes allows constitutive WNT
signaling in colorectal cancer. Nat Genet. 36:417–422. 2004.
|
|
26
|
Quan H, Zhou F, Nie D, et al: Hepatitis C
virus core protein epigenetically silences SFRP1 and enhances HCC
aggressiveness by inducing epithelial-mesenchymal transition.
Oncogene. 2013.
|
|
27
|
Fukui T, Kondo M, Ito G, et al:
Transcriptional silencing of secreted frizzled related protein 1
(SFRP 1) by promoter hypermethylation in non-small-cell lung
cancer. Oncogene. 24:6323–6327. 2005.
|
|
28
|
Shih YL, Shyu RY, Hsieh CB, et al:
Promoter methylation of the secreted frizzled-related protein 1
gene SFRP1 is frequent in hepatocellular carcinoma. Cancer.
107:579–590. 2006.
|
|
29
|
Park IY, Sohn BH, Yu E, et al: Aberrant
epigenetic modifications in hepatocarcinogenesis induced by
hepatitis B virus X protein. Gastroenterology. 132:1476–1494.
2007.
|
|
30
|
Sasaki Y: Does oxidative stress
participate in the development of hepatocellular carcinoma? J
Gastroenterol. 41:1135–1148. 2006.
|
|
31
|
Tong A, Gou L, Lau QC, et al: Proteomic
profiling identifies aberrant epigenetic modifications induced by
hepatitis B virus X protein. J Proteome Res. 8:1037–1046. 2009.
|
|
32
|
Zhao C, Bu X, Zhang N and Wang W:
Downregulation of SFRP5 expression and its inverse correlation with
those of MMP-7 and MT1-MMP in gastric cancer. BMC Cancer.
9:2242009.
|
